First gene therapy for β-thalassemia approved
Bluebird Bio has been granted the go-ahead to market its gene therapy for the blood disorder β-thalassemia. Zynteglo gained conditional market approval from the European Commission in June to treat transfusion-dependent β-thalassemia in patients 12 years and older who have no other treatment options. Image by lisichik from Pixabay Read more at Nature… The post [...]







